Annals of Oncology @Annals_Oncology Twitter profile

Pinned Tweet

Annals of Oncology

4 years

Stay up to date with the very latest from Annals of Oncology. Register for free to receive content and issue alerts by e-mail or subscribe to our RSS

12

8

47

Last Seen Profiles

@jennyzheng719

@pengen_stw

@KasihLudah

@jandakembangstw

@_BryanGB

@dagster

@Rajendra4BJP

@BdwrAlms

@dragonsbt

@EIPGeu

@himagaeee

@HuskyHaul

@dotbg

@studycoinsol

@timikimitin

@hijabjilbab1

@AlCaponeJr_

@JPiresGlobal

@TheCryptoTomato

@sinmay01

@jandakembangstw

@bukanpakpulici

@srvthunderbirds

@Jenson135440

@KrullMatt

@assistafilmebr

@VmaniakJ

@umfrenesi

@GoArrows

@leoaraoficial

@jandakembangstw

@AZHSFBCC

@pengen_stw

@johnny_3360

@Farsm08

@whotfisanthem

Annals of Oncology

@Annals_Oncology

2 years

We are happy to announce that the Annals of Oncology Impact Factor has reached an all-time high 📈 at 51.769, ranking the journal #5 out of 245 in the Oncology category! @myESMO

8

52

345

Annals of Oncology

@Annals_Oncology

3 years

Congratulations to our Editor-in-chief @FAndreMD for receiving today at #SABCS21 the @AACR Outstanding Investigator Award for Breast Cancer Research 👏👏👏 @SABCSSanAntonio @BCRFcure @GustaveRoussy @myESMO

11

23

208

Annals of Oncology

@Annals_Oncology

2 years

In Annals of Oncology, results from the German 🇩🇪 #PrecisionMedicine 🧬🎯💊 NCT/DKTK MASTER trial inform on the association of cancer perdisposing genes and rare cancer

0

67

180

Annals of Oncology

@Annals_Oncology

8 months

Artificial intelligence as a tool to identify predictive biomarker in immuno-oncology: this systematic review by @PrelajArsela and coll. in Annals of Oncology encompasses genomics, radiomics, pathomics, real-world and multimodal data

3

76

179

Annals of Oncology

@Annals_Oncology

1 year

Cancer of unknown primary (CUP) has a low prevalence but a high mortality rate. In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of CUP:

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Cancer of unknown primary (CUP) is defined as a carcinoma or undifferentiated neoplasm for which a standardised diagnostic work-up fails to identify the primary tumour responsible for metastatic...

www.annalsofoncology.org

0

56

154

Annals of Oncology

@Annals_Oncology

3 years

How to tailor adjuvant chemotherapy in HR+/HER2- early #BreastCancer ? Do not miss this recent manuscript in Annals of Oncology that provides input based on the results of TAILOR-x, MINDACT and Rx-PONDER #bcsm @JulesBordet @KalinskyKevin @DrEricWiner

2

67

147

Annals of Oncology

@Annals_Oncology

4 years

📣New in Annals of Oncology, the @myESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of Prostate Cancer #pcsm

2

63

141

Annals of Oncology

@Annals_Oncology

4 years

With #ESMOBreast20 just around the corner, Annals of Oncology has prepared a collection of most read #BreastCancer articles. Free access using this link: #bcsm @myESMO

0

74

138

Annals of Oncology

@Annals_Oncology

3 years

Abemaciclib + endocrine therapy for early breast cancer was approved by @FDAOncology based on the monarchE study. Results of the the primary outcome analysis presented at the #ESMOVirtualPlenary are available #openaccess in @Annals_Oncology #bcsm

1

69

131

Annals of Oncology

@Annals_Oncology

9 months

In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of pancreatic cancer 👇 @icl_lorraine @DucreuxMichel @ArndtVogel @EileenMOReilly @DrAngelaLamarca

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Details on incidence and epidemiology are covered in the Supplementary Material Section 1, available at https://doi.org/10.1016/j.annonc.2023.08.009.

www.annalsofoncology.org

0

58

129

Annals of Oncology

@Annals_Oncology

4 years

Out in Annals of Oncology, the @myESMO clinical practice guidelines for the management of bone health in cancer (including early breast cancer and prostate cancer): #bcsm #pcsm

1

64

119

Annals of Oncology

@Annals_Oncology

1 year

Now available in Annals of Oncology, the @myESMO Clinical Practice Guideline for the diagnosis and management of venous thromboembolism in patients with cancer

0

50

113

Annals of Oncology

@Annals_Oncology

4 years

Letter to the Editor in Annals of Oncology reporting the successful treatment of a patient with cancer and severe pulmonary manifestations of #COVID19 with Tocilizumab, anti-IL6 receptor moAb used for treating CRS seen with CAR-Ts @MichotJM @GustaveRoussy

2

73

109

Annals of Oncology

@Annals_Oncology

22 days

Now available #OpenAccess in Annals of Oncology, recommendations by the @myESMO Precision Medicine Working Group for the use of NGS for patients with advanced cancer in 2024 🧬Expanding indications 🧬CUP & tissue-agnostic situations 🧬Best practice

0

63

132

Annals of Oncology

@Annals_Oncology

2 years

Invasive lobular carcinoma (ILC) represents 15% of breast cancers & carries distinct pathological & clinical characteristics. This review in Annals of Oncology highlights diagnostic & treatment strategies for ILC. @VanBaelenKaren @ChristineDesme2 #bcsm

Current and future diagnostic and treatment strategies for patients with invasive lobular breast...

Invasive lobular breast cancer (ILC) is the second most common type of breast cancer after invasive breast cancer of no special type (NST), representing up to 15% of all breast cancers.

www.annalsofoncology.org

2

48

104

Annals of Oncology

@Annals_Oncology

4 years

📣Just out in Annals of Oncology, the @myESMO Clinical Practice Guidelines for fertility preservation and post-treatment pregnancies in post-pubertal patients with cancer @matteolambe @fedrophd @IDemeestere

1

69

105

Annals of Oncology

@Annals_Oncology

4 years

This review published in the September issue of Annals of Oncology provides an update on the use of PARP inhibitors in ovarian cancer #gyncsm

0

47

102

Annals of Oncology

@Annals_Oncology

3 years

Tumor mutational burden (TMB) has emerged as a tissue-agnostic predictive biomarker for immunotherapy. Empirical variability exists across panel assays. The TMB Consortium investigated factors contributing to variability in this #OpenAccess paper

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the...

Tumor mutational burden (TMB) measurements aid in identifying patients who are likely to benefit from immunotherapy; however, there is empirical variability across panel assays and factors contribu...

www.annalsofoncology.org

2

48

101

Annals of Oncology

@Annals_Oncology

4 years

The new impact factor has been released and we are happy to see that the Annals of Oncology IF has increased to an all-time high of 18.274! 📈

1

18

102

Annals of Oncology

@Annals_Oncology

4 years

On June 16th 2020, @FDAOncology granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with tumor mutational burden-high 🧬(TMB-H). In Annals of Oncology a pro and con editorial debate

0

40

95

Annals of Oncology

@Annals_Oncology

4 years

Today we’re pleased to announce the launch of our brand new website! The January 2020 edition of Annals of Oncology has also arrived. All articles in the issue are free to read @myesmo

2

34

93

Annals of Oncology

@Annals_Oncology

4 years

Adrenocortical carcinoma (ACC) and malignant phaeochromocytoma are rare malignancies that require multidisciplinary management. You can find the ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up in Annals of Oncology: @myESMO

0

48

93

Annals of Oncology

@Annals_Oncology

3 years

TMB-H is approved as a histology-agnostic biomarker for therapy with an immune checkpoint inhibitor. This study published #openaccess in Annals of Oncology shows that context matters: response is not universal in all tumor types @MDAndersonNews @NKI_nl

2

34

89

Annals of Oncology

@Annals_Oncology

4 years

NTRK gene fusions 🧬 are oncogenic and highly actionable 💊. Just out and #openaccess in Annals of Oncology: expert recommendations from the World Sarcoma Network for the diagnosis and management of TRK fusion sarcomas @DrSarcoma @jeanyvesblay

0

44

88

Annals of Oncology

@Annals_Oncology

1 year

In Annals of Oncology, a report on the STING (NCT04932525) study in which patients with advanced cancer had molecular profiling using a ctDNA sequencing assay 🩸🧬 and were assigned matched therapy 💊 as per a molecular tumor board. @GustaveRoussy @ArBayle

0

43

89

Annals of Oncology

@Annals_Oncology

3 years

Pembrolizumab in early TNBC was recently evaluated by @FDAOncology after the initial results of KEYNOTE-522. This review in the March 2021 issue by @AliceFranzoi and coll. provides an overview on IO in early breast cancer #bcsm @JulesBordet @institut_curie

1

41

87

Annals of Oncology

@Annals_Oncology

3 years

Cancer of unknown primary (CUP) is defined as metastatic cancer for which identification of the primary site was not possible and accounts for 2% to 5% of cancer cases. Results of a phase 2 study of Nivolumab in CUP (including biomarker analyses) 👇

1

38

87

Annals of Oncology

@Annals_Oncology

3 years

Now in press 📰 in Annals of Oncology: the consensus 🤝 guidelines for the treatment of early breast cancer from the 17th St Gallen International Breast Cancer Consensus Conference in 2021 #bcsm @DrHBurstein @curijoey @DrEricWiner @MichaelGnant

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen...

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-ann...

www.annalsofoncology.org

0

50

88

Annals of Oncology

@Annals_Oncology

2 years

Following the presentation at the @myESMO Virtual Plenary, the OS analyses from the OlympiA phase III trial of adjuvant olaparib in patients with gBRCA1/2 & high risk, early breast cancer are now available #OpenAccess in Annals of Oncology #bcsm

0

38

86

Annals of Oncology

@Annals_Oncology

10 months

ctDNA 🩸🧬🧪 analyses as a predictive biomarker in early-stage triple-negative breast cancer: the association of ctDNA dynamics with RCB during neoadjuvant therapy in the TBCRC 030 clinical trial @DFCI_BreastOnc @broadinstitute #bcsm

0

31

82

Annals of Oncology

@Annals_Oncology

3 years

The @myESMO ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer is now available in @Annals_Oncology 👉 #bcsm @ALEDIGNUS12 @FAndreMD

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metast...

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have been reported with appropriate therapeutic strategies.1-8 Systemic therapy is the standard-of-care in MBC but...

www.annalsofoncology.org

0

35

78

Annals of Oncology

@Annals_Oncology

2 years

In Annals of Oncology, review discussing: 🐉Resistance to targeted therapies 🐉Mixed responses on treatment 🐉Tumor subclones 🐉Means of monitoring 🐉Tailored N-of-1 combos @jacobadashek @VivekSubbiah @BenWestphalen @ANaingMD @Dr_R_Kurzrock

0

42

76

Annals of Oncology

@Annals_Oncology

2 years

The use of NGS on DNA🧬 from tissue or liquid biopsies is now well established in the management of patients with cancer. In this Letter to the Editor, @ArBayle and coll. present the data from cases tested with both modalities in PRISM 🇫🇷

1

35

76

Annals of Oncology

@Annals_Oncology

3 years

Immune-related adverse events (irAEs) can occur more than 1 year after starting anti-PD1 therapy. This manuscript describes the characteristics and course of delayed irAEs in a series of 118 patients treated for melanoma @ProfGLongMIA @sandrineaspesla

0

34

77

Annals of Oncology

@Annals_Oncology

5 years

Just out in Annals of Oncology: you can now read all of the abstracts from #ESMO19 online in the @myESMO Abstract Book of the 44th Congress

0

42

75

Annals of Oncology

@Annals_Oncology

2 years

In this new review in Annals of Oncology, @FCortiula and coll. discuss immunotherapy in unresectable stage III NSCLC: ✅State of the art and rationale ✅Treatment synergisms ✅Ongoing clinical trials ✅Unmet needs and future biomarkers #LCSM

0

33

74

Annals of Oncology

@Annals_Oncology

3 years

Early detection could improve cure rates, mainly in cancers without screening modalities. 📢 Just out in Annals of Oncology : Clinical validation of a targeted methylation-based multi-cancer early detection test 🩸🧬 using an independent validation set

1

29

74

Annals of Oncology

@Annals_Oncology

2 years

In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of biliary tract cancer @ArndtVogel @DucreuxMichel

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Biliary tract cancers (BTCs) account for <1% of all human cancers. Cholangiocarcinoma (CCA) is the second most common primary liver cancer after hepatocellular carcinoma (HCC), accounting for...

www.annalsofoncology.org

0

38

72

Annals of Oncology

@Annals_Oncology

2 years

Just out in Annals of Oncology, results of Pooled analyses from four 1L Nivolumab + Ipilimumab studies in NSCLC including landmark analyses of OS by response status at 6 months and by tumor-burden reduction #LCSM

0

30

74

Annals of Oncology

@Annals_Oncology

3 years

With the increase 📈 in the number of approved targeted therapies 🎯💊 , @VPrasadMDMPH and coll. evaluated the uptake and response to genome-targeted oncology drugs in the US using mortality data from @AmericanCancer and the @FDAOncology labels

0

31

73

Annals of Oncology

@Annals_Oncology

3 years

In Press in Annals of Oncology: after correction for clonal hematopoiesis, liquid biopsies using ctDNA dynamics 🧪🧬 post-resection of esophageal adenocarcinoma provides prognostic information that could potentially inform adapted therapeutic strategies

1

26

72

Annals of Oncology

@Annals_Oncology

4 years

Annals of Oncology manuscript on data from three hospitals in Wuhan, China, describing the clinical characteristics of patients with cancer infected by #COVID19 #Covid_19

2

66

72

Annals of Oncology

@Annals_Oncology

3 years

Now available in Annals of Oncology, the @myESMO clinical practice guidelines for the diagnosis, treatment and follow-up of anal cancer, a rare disease accounting for less than 1% of all cancers

0

30

72

Annals of Oncology

@Annals_Oncology

2 years

Both somatic and germline genomic alterations 🧬 can guide management in solid tumors 🎯💊 This original article available #openaccess shows that 10.5% of pathogenic germline variants in clinically relevant genes can be missed by tumor-only sequencing.

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

Tumor-only sequencing, implemented for the identification of somatic variants, is oftentimes used for the detection of actionable germline variants. We sought to determine whether tumor-only sequen...

www.annalsofoncology.org

1

35

72

Annals of Oncology

@Annals_Oncology

4 years

A HLA-corrected TMB algorithm (TMB in combination with loss of heterozygosity of HLA) to better select patients who may benefit from immunotherapy. Read this #EditorsChoice #openaccess paper in Annals of Oncology #LCSM #ImmunoOnc

1

33

70

Annals of Oncology

@Annals_Oncology

4 years

NRG1 fusions are rare oncogenic genomic alterations 🧬 with potentially effective therapeutic options 💊. Learn more in the paper published #openaccess in Annals of Oncology #lcsm @StephenVLiu @alexdrilon @CadranelJ

1

28

69

Annals of Oncology

@Annals_Oncology

4 years

Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up @myESMO @EANOassociation

0

40

69

Annals of Oncology

@Annals_Oncology

4 years

Sacituzumab Govitecan (SG), an anti-Trop2 ADC, is approved by the @FDAOncology for metastatic TNBC. Just out #openaccess in Annals of Oncology: encouraging activity for SG in patients with pretreated HR+/HER2- MBC #bcsm @ABhealer108 @stolaney1

2

33

68

Annals of Oncology

@Annals_Oncology

2 years

De-intensification of cancer treatments is an important field of clinical research in disease settings that have seen an improvement in patient outcomes. @myESMO via the Precision Medicine WG proposes a 3-tier classification to guide these efforts @darioT_

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification

The landscape of clinical trials testing risk-adapted modulations of cancer treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority have been used; however, no...

www.annalsofoncology.org

0

33

67

Annals of Oncology

@Annals_Oncology

4 years

Just out and #openaccess in Annals of Oncology: Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer #lcsm @StephenVLiu @LeciaSequist

0

32

68

Annals of Oncology

@Annals_Oncology

2 years

Nivolumab + ipilimumab improved OS vs chemo as 1st line treatment for unresectable malignant pleural mesothelioma in the CheckMate 743 ph 3 study. Updated data with 3-year follow-up have been published #openaccess in Annals of Oncology @peters_solange

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant...

In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant...

www.annalsofoncology.org

2

20

67

Annals of Oncology

@Annals_Oncology

1 year

❓Can PARP inhibition improve overall survival (OS) in HRD+ newly diagnosed advanced ovarian cancer? 👉The prespecified final OS analysis from the PAOLA-1/ENGOT-ov25 study testing olaparib + bevacizumab 1L maintenance is reported in Annals of Oncology

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results...

In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer...

www.annalsofoncology.org

0

22

65

Annals of Oncology

@Annals_Oncology

2 years

The quest for a pan-cancer predictive biomarker of ICB benefit beyond TMB-H continues. @barechey and coll. performed a pan-cancer gene expression meta-analysis identifying PredictIO, a gene expression signature with consistent predictive potential. ➡️

2

22

66

Annals of Oncology

@Annals_Oncology

4 years

Liquid biopsies using ctDNA 🩸🧪🧬as a predictor of outcome during and after neoadjuvant chemotherapy for early #BreastCancer : ❌on-treatment ctDNA+ was associated with residual disease ✅post-therapy ctDNA- was associated with a better outcome #bcsm

1

37

65

Annals of Oncology

@Annals_Oncology

2 years

Multiple driver alterations are drug targets in advanced NSCLC 🫁. With the emergence of allele-specific KRAS inhibitors, @jia_luo and coll. investigate clinicopathologic, genomic, & immunophenotypic characteristics of NSCLC with KRAS G12D mutations #LCSM

0

30

64

Annals of Oncology

@Annals_Oncology

4 years

The Avelumab/Axitinib combo was approved for the treatment of metastatic renal cell carcinoma in the 1st line setting following the results of JAVELIN Renal 101. Updated efficacy data are reported in Annals of Oncology @DrChoueiri @AlbigesL #KidneyCancer

0

45

65

Annals of Oncology

@Annals_Oncology

4 years

In the PROMISE-meso randomised phase III trial now published in Annals of Oncology, Pembrolizumab does not improve PFS nor OS over single-agent chemotherapy in relapsed malignant pleural mesothelioma @DrSanjayPopat @peters_solange

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy...

Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemothe...

www.annalsofoncology.org

2

34

66

Annals of Oncology

@Annals_Oncology

6 years

We are pleased to reveal Annals of Oncology’s new Impact Factor is 13.926! We’ve created a collection of highly cited articles which contributed to the rise to explore online @myESMO

3

17

66

Annals of Oncology

@Annals_Oncology

4 years

#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: #LCSM @GLambertiMD @meyersonlab

0

38

66

Annals of Oncology

@Annals_Oncology

5 years

A decade of clinical development of PARP inhibitors in perspective #OpenAccess

0

30

63

Annals of Oncology

@Annals_Oncology

2 years

The @FDAOncology approved Dabrafenib + Trametinib in anaplastic thyroid cancer with a BRAF V600E mutation based on results from the phase 2 ROAR "basket" trial. Updated results including long-term survival are now available #openaccess 👇 @VivekSubbiah

0

29

63

Annals of Oncology

@Annals_Oncology

2 years

Can acetaminophen, a widely used analgesic, impact the efficacy of immune checkpoint inhibitors (ICIs)? @AItalianoMD and coll. studied the correlation of acetaminophen exposure with clinical outcome in 3 independent cohorts of patients treated with ICIs

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Acetaminophen (APAP) use has been associated with blunted vaccine immune responses. This study aimed to assess APAP impact on immunotherapy efficacy in patients with cancer.

www.annalsofoncology.org

0

28

63

Annals of Oncology

@Annals_Oncology

2 years

The pivotal study of Tucatinib (HER2CLIMB) in patients with HER2+ metastatic breast cancer allowed the inclusion of patients with untreated and progressive brain metastases. The final overall survival analysis is available👇 @curijoey @DrEricWiner #bcsm

1

23

62

Annals of Oncology

@Annals_Oncology

4 years

Do not miss this #EditorsChoice paper in the November 2020 issue of Annals of Oncology - Recommendations for the use of next-generation sequencing (NGS) 🧬 for patients with metastatic cancers: a report from the @myESMO Precision Medicine Working Group

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic...

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no...

www.annalsofoncology.org

1

27

62

Annals of Oncology

@Annals_Oncology

4 years

The IMpassion130 trial of atezolizumab + nab-paclitaxel in metastatic TNBC led to the regulatory approval of the first immunotherapy in #BreastCancer . PROs analyses from the phase III study now published in the May 2020 issue of Annals of Oncology #bcsm

0

28

59

Annals of Oncology

@Annals_Oncology

4 years

Just out in Annals of Oncology 📣, does androgen deprivation therapy (ADT) 💊 have a protective effect against infection with #COVID19 🦠? Data from the Veneto region 🇮🇹 and the biological rationale behind this hypothesis in this free access manuscript:

1

32

61

Annals of Oncology

@Annals_Oncology

3 years

Post-operative chemoradiotherapy in the US and perioperative chemotherapy in Europe have been the standards for the treatment of gastric cancer. The CRITICS study published in Annals of Oncology randomly allocated patients to one of both strategies:

Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the...

The Intergroup 0116 and the MAGIC trials changed clinical practice for resectable gastric cancer in the Western world. In these trials, overall survival improved with post-operative chemoradiotherapy...

www.annalsofoncology.org

1

28

62

Annals of Oncology

@Annals_Oncology

3 years

Many presentations at #ESMO21 cited the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Find more on ESCAT and #PrecisionMedicine 🧬🎯💊in these @Annals_Oncology resources:

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic...

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no...

www.annalsofoncology.org

0

23

61

Annals of Oncology

@Annals_Oncology

1 year

❓Can single-agent or dual immunotherapy improve outcomes compared to the EXTREME regimen (platinum-based chemo + cetuximab) as 1st-line treatment for R/M HNSCC? ➡️Results of the KESTREL randomized Ph3 trial are available #OpenAccess in Annals of Oncology

0

19

61

Annals of Oncology

@Annals_Oncology

2 years

RET fusions are rare but highly actionable genomic 🧬 alterations in NSCLC & other tumor types. In Annals of Oncology, @GriesingerFrank and coll. report an updated analysis on patients with RET fusion+ NSCLC from the ARROW multi-cohort phase I/II study

0

23

61

Annals of Oncology

@Annals_Oncology

6 months

In Annals of Oncology, the @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of early breast cancer #bcsm

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Global estimates indicated 2.3 million new cases of breast cancer in 2020, contributing to nearly 12% of all new cancer cases, with 685 000 deaths in the same year.1 Breast cancer detection has...

www.annalsofoncology.org

2

32

61

Annals of Oncology

@Annals_Oncology

1 year

In Annals of Oncology, genomic characterization 🧬of HR+ breast cancer in very young women enrolled in SOFT shed light on unfavourable prognostic features potentially informing future therapeutic strategies @LoiSher @etop_ibcsg #bcsm

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2−) early breast cancer (EBC) have higher rates of recurrence and...

www.annalsofoncology.org

0

37

60

Annals of Oncology

@Annals_Oncology

4 years

Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the @myESMO Precision Medicine Working Group 🧬🎯 @demattosarruda

0

31

59

Annals of Oncology

@Annals_Oncology

1 year

Trastuzumab Deruxtecan was approved for the treatment of HER2+ MBC after 1 prior anti-HER2-based regimen following the results of DB03. In Annals of Oncology, @curijoey and colleagues report on PROs and hospitalization data from the phase 3 clinical trial.

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast...

In the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan (T-DXd) showed superior progression-free survival and overall survival versus trastuzumab emtansine (T-DM1) and manageable safety in...

www.annalsofoncology.org

1

20

59

Annals of Oncology

@Annals_Oncology

3 years

In this new article in Annals of Oncology, @CharlesSwanton at al. review and discuss results from three genotype matched platform trials, drawing a roadmap for a future precision medicine strategy 🧬🎯💊

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine...

Building on the success of targeted therapy in certain well-defined cancer genotypes, three platform studies—NCI-MATCH, LUNG-MAP and The National Lung Matrix Trial (NLMT)—have attempted to discover...

www.annalsofoncology.org

1

20

59

Annals of Oncology

@Annals_Oncology

10 months

Novel anti-HER2 ADCs demonstrated compelling activity with an objective response rate of 37% across a large spectrum of tumor types with HER2 expression. This article in Annals of Oncology reports on HER2 status in different cancers including breast & GEJ

1

17

59

Annals of Oncology

@Annals_Oncology

2 years

Randomized clinical trial designs are sometimes not feasible. This review article in Annals of Oncology discusses the concept of external control arms as a way to circumvent this caveat. @pmishrakalyani @DrJuliaBeaver @realrickpazdur

External control arms in oncology: current use and future directions

Although randomized control trials allow for a comparison of treatment arms with minimal concern for confounding by known and unknown factors, a randomized study is not feasible in certain disease...

www.annalsofoncology.org

1

22

58

Annals of Oncology

@Annals_Oncology

4 years

Alpelisib (α-selective PI3K inhibitor) is approved by the FDA in combination with ET for ER+/HER2- MBC with a PIK3CA mutation. Read in Annals of Oncology on the time course and management of AEs from the pivotal phase 3 trial #bcsm @hoperugo @FAndreMD

2

27

56

Annals of Oncology

@Annals_Oncology

3 years

CAR-T cells targeting solid cancers have had limited success so far for multiple reasons, including their poor long-term persistence and proliferation. This review discusses early-phenotype CAR-Ts as a strategy to overcome this caveat @PeterMacCC

0

20

55

Annals of Oncology

@Annals_Oncology

4 years

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma #melsm #EditorsChoice @myesmo

0

32

56

Annals of Oncology

@Annals_Oncology

1 year

With immune checkpoint inhibitors & targeted therapies approved in the adjuvant setting of stage III melanoma, the neoadjuvant approach offers several advantages. Just out 👇, survival updates of neoadjuvant IPI + NIVO in the OpACIN & OpACIN-neo trials

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the...

Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in patients with macroscopic stage III melanoma. These response rates translated to high short-term survival rates. However, data...

www.annalsofoncology.org

1

18

55

Annals of Oncology

@Annals_Oncology

4 years

The @myESMO World Congress on Gastrointestinal Cancer 2020 (virtual) starts today. Check this link for a freely available collection of GI articles #crcsm #esocsm #hpbcsm #pancsm #stcsm

0

36

55

Annals of Oncology

@Annals_Oncology

4 years

Just out📣 in Annals of Oncology, the @myESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Localised Colon Cancer #crcsm @TaberneroJosep

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Colorectal cancer (CRC) is the third most common tumour in men and the second in women, accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and differs greatly between...

www.annalsofoncology.org

0

33

56

Annals of Oncology

@Annals_Oncology

4 years

Could the gut microbiome🦠 be linked to the outcome of treatment with neoadjuvant chemo-radiotherapy 💉☢️ in rectal cancer ? You can find out more in this #openaccess paper in Annals of Oncology: @PaoloNuciforo @rdienstmann @TaberneroJosep #CRCSM

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally...

Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer. Nevertheless, only limited data exist about the role of this bacterium...

www.annalsofoncology.org

0

40

56

Annals of Oncology

@Annals_Oncology

1 year

The intestinal microbiome 🦠 is associated with response to immune checkpoint inhibitors in patients with cancer. The FIH MET4-IO study investigated MET4, an orally-delivered 30-species microbial consortium, with ICIs as a replacement to fecal microbiota.

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint...

The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICIs) in humans and causally implicated in ICI responsiveness in animal models. Two recent human trials...

www.annalsofoncology.org

0

31

56

Annals of Oncology

@Annals_Oncology

4 years

In his talk on priorities in #BreastCancer in the next 10 years at #ESMOBreast20 , Annals of Oncology EiC @FAndreMD discusses the promise of early detection of cancer using liquid biopsies. The CCGA & @GrailBio landmark paper is available #openaccess #bcsm

0

18

56

Annals of Oncology

@Annals_Oncology

4 years

How to manage advanced #BreastCancer in 2020: discover the 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) #bcsm @ESOncology @myESMO

2

31

54

Annals of Oncology

@Annals_Oncology

9 months

#OpenAccess in Annals of Oncology, results of the ATALANTE-1 RCT investigating OSE2101, a vaccine inducing cytotoxic T lymphocytes against 5 tumor-associated antigens (HER-2, CEA, MAGE 2, MAGE 3 and p53) in HLA-A2+ NSCLC 🫁 after failure of an ICI #lcsm

1

24

56

Annals of Oncology

@Annals_Oncology

2 years

Just out in Annals of Oncology, the @myESMO recommendations on the use of ctDNA assays 💉🩸 🧬 for patients with cancer: from technical considerations to potential clinical indications including evidence for clinical utility @jpascualmd #PrecisionMedicine

0

26

54

Annals of Oncology

@Annals_Oncology

4 years

Dr Romano from @GustaveRoussy presents at #ESMO20 the classification of genomic alterations from MOSCATO & MATCHR using @myESMO ESCAT. In Annals of Oncology, the recommendations of the @myesmo PMWG for the use of NGS for patients with metastatic cancers

3

31

53

Annals of Oncology

@Annals_Oncology

1 month

Presented by @RebeccaDSing at #ESMOBreast24 w/ simultaneous publication in Annals of Oncology 1st results of Impassion132 showing no benefit of adding #atezoliyumab to 1st line CT in pts w/ advanced #TNBC relapsing <12months. #AnnOnc #BreastCancer

0

23

55

Annals of Oncology

@Annals_Oncology

6 years

One of our most read articles of the year: Drastic decrease of the HIV reservoir in a patient treated with #nivolumab for lung cancer

0

29

53

Annals of Oncology

@Annals_Oncology

3 years

Multi-region WES 🧬 reveals an intratumoural metastasis in this case of combined lung SCLC 🫁 🔹The SCLC harbored a RB1 mutation among other drivers 🔹The adenocarcinoma component harbored a KRAS G12C mutation @cusm_muhc @pierrefiset @sorin_mark #LCSM

0

21

53

Annals of Oncology

@Annals_Oncology

3 years

Just published in Annals of Oncology: study describing the genomic landscape 🧬of gastroesophageal adenocarcinoma depending on PDL1 expression levels. Association of genomic alterations and outcome on immunotherapy are described

0

27

51

Annals of Oncology

@Annals_Oncology

4 years

In the November 2020 issue of Annals of Oncology, the @EHNSnews - @myESMO - @ESTRO_RT Clinical Practice Guidelines for diagnosis, treatment and follow-up of squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx #hncsm

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO...

Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and occurs in the oral cavity, pharynx and larynx. Nasopharyngeal carcinoma (NPC) is a disease with unique features...

www.annalsofoncology.org

1

23

50

Annals of Oncology

@Annals_Oncology

5 years

While immunotherapy has become a central component of first-line treatment of most patients with advanced non-small-cell #lungcancer , important questions remain about how treatment should be managed for individual patients. #EditorsChoice

0

37

53

Annals of Oncology

@Annals_Oncology

2 years

Tusamitamab ravtansine (SAR408701) is an antibody-drug conjugate (ADC) targeting CEACAM5 with a maytansinoid (DM4) payload. Results of the first-in-human dose escalation study are available in Annals of Oncology @TaberneroJosep @Philippe_Bedard

2

20

53

Annals of Oncology

@Annals_Oncology

4 years

Just out 📣 in Annals of Oncology, results of TBCRC 030, a phase II study of preoperative cisplatin vs paclitaxel evaluating the predictive value of the HRD biomarker in triple-negative #BreastCancer #bcsm @elmayermd @mfrimawi @awolff

0

24

51

Annals of Oncology

@Annals_Oncology

9 months

Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 #bcsm

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International...

The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna, Austria, assessed significant new findings for local and systemic therapies for early breast cancer with a...

www.annalsofoncology.org

0

13

51

Annals of Oncology

@Annals_Oncology

3 years

📣Just out in Annals of Oncology: European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer Key highlights include: ✅ A decrease in total cancer mortality rates ❌ No decrease in pancreatic cancer mortality

1

27

52